Legal Marijuana Industry Shows Versatility and Growth, Pot Inc. Leaders Say
Beyond its recreational use, the burgeoning legal cannabis industry is demonstrating its potential in medicinal applications and professional business practices.
The legal marijuana industry, valued at $50 billion, is poised for further expansion following the federal government's reclassification of cannabis as a Schedule 3 drug, which allows for prescription by doctors. This shift signifies that the industry's scope extends beyond recreational use, encompassing medicinal benefits and offering valuable lessons to corporate America in customer service.
Evolving Perceptions and Applications
Despite initial skepticism from some quarters, including a personal aversion to the smell of cannabis and concerns about its widespread presence, the industry is proving to be multifaceted. Beyond traditional smoking products, consumers can access alternatives like gummies for discreet consumption and ointments for pain relief. Furthermore, cancer patients are increasingly benefiting from its therapeutic properties.
Professional Operations and Sustainable Practices
Businesses within the legal cannabis sector are prioritizing professional operations and customer experience. One prominent company, Glass House Brands, which recently listed on the NYSE under the symbol GLAS, operates a large-scale cultivation facility in Camarillo, California. The company's president, Graham Farrar, highlighted the farm's sustainable practices, noting that it is powered by solar panels and on-site natural gas cogeneration plants that utilize waste heat for greenhouses and supply carbon dioxide to the plants. The facility also maintains its own water supply, reducing reliance on external sources.
Farrar, who has a background in technology and farming, acknowledged the risks associated with smoking cannabis but emphasized the scientific evidence supporting its safety relative to alternatives. He also pointed to the growing availability of edibles as a non-smoking option.
Market Potential and Future Outlook
The reclassification of cannabis as a Schedule 3 drug, driven by its medicinal applications, is seen as a significant step toward full federal legalization. Proponents argue that increased legalization will lead to more robust regulation, helping to keep cannabis away from minors, while also expanding access to banking services for growers. Despite market volatility, with GLAS shares experiencing a significant decline since their IPO, the underlying public demand for cannabis remains strong, suggesting continued growth potential for the industry.